ChanningJudithPallerMD

Oncology • Washington, DC

Genitourinary Oncology, Hematologic Oncology

Assistant Professor of Oncology, Johns Hopkins University School of Medicine

Join to view full profile

Dr. Paller is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Paller's full profile

Already have an account?

Office
5255 Loughboro Rd NW
Washington, DC 20016
Phone+1 410-955-7963

Fax+1 202-660-6501

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2008 - 2011
Johns Hopkins UniversityResidency, Internal Medicine, 2005 - 2008
Harvard Medical SchoolClass of 2005, MD

Certifications & Licensure

FL State Medical License 2021 - Present
VA State Medical License 2021 - 2026
MD State Medical License 2008 - 2025
DC State Medical License 2012 - 2024
PA State Medical License 2020 - 2022
AL State Medical License 2020 - 2020
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Medical OncologyInternal Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer Start of enrollment: 2011 Jul 01
Completed
Phase 1, Phase 2
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Trial of Mistletoe Extract in Patients With Advanced Solid Tumors Start of enrollment: 2017 Mar 01
Completed
Phase 1
Muscadine Plus (MPX) In Men With Prostate Cancer Start of enrollment: 2018 Oct 30
Terminated
Phase 3
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer Start of enrollment: 2016 May 03
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer Start of enrollment: 2022 Sep 22
Recruiting
Not Applicable
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Intratumoral heterogeneity drives acquired therapy resistance in a patient with metastatic prostate cancer.
Dena P Rhinehart, Jiaying Lai, David E Sanin, Varsha Vakkala, Adrianna Mendes
NPJ Precision Oncology. 2024-12-02
Initial Experience with [Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction.
Andrei Gafita, Andrew Voter, Somya Shesadri, Avery Spitz, Catherine H Marshall
Journal of Nuclear Medicine. 2024-11-01
Efficacy and Toxicity of [Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase ...
Vishnu Murthy, Andrew F Voter, Kathleen Nguyen, Martin Allen-Auerbach, Lucia Chen
Journal of Nuclear Medicine. 2024-11-01

Journal Articles

Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer
Channing J Paller, Otis Brawley, JAMA Oncology
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer
Emmanuel S Antonarakis, Ashley E Ross, Michael A Gorin, Samuel R Denmeade, Channing J Paller, Kenneth J Pienta, Mario A Eisenberger, JAMA Oncology
TGF‐Β Receptor I Inhibitor Enhances Response to Enzalutamide in a Pre‐Clinical Model of Advanced Prostate Cancer
Channing Paller, Cameron A Wade, The Prostate

Lectures

FACTS: Factors affecting combination trial success.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Enzalutamide May Have Slight Survival Advantage over Abiraterone for mCRPCAugust 19th, 2024
Johns Hopkins Study Highlights Promise of IV Mistletoe Extract for Cancer Therapy – the Mercury NewsMarch 24th, 2023
Johns Hopkins Study Highlights Promise of IV Mistletoe Extract for Cancer Therapy – Twin CitiesMarch 24th, 2023
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

External Links

Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/channing-paller